MedTrace Logo

A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus

NCT00203151 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2011-04-12

No results posted yet for this study

Summary

It is thought that Edratide may be able to reduce the symptoms of SLE.

Conditions

Interventions

DRUG

edratide

0.5 mg, 1.0 mg, 2.5 mg injection once weekly

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Dan Goldsatub, Ph.D. · Teva Branded Pharmaceutical Products R&D, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2007-02-28
Completion
2007-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203151 on ClinicalTrials.gov